Samples from 11 MS and three control participants (Batch 1) were analyzed using the antibodies in Supplementary Data 1, excluding the antibody against CCR2, and for samples for eight MS and five control participants (Batch 2) the antibody against CCR2 was included. This evidence concerns the gene CCR2 and myeloid sarcoma.